Diffuse Large B-Cell Lymphoma Market Size was USD 3700 Million in 2021

Diffuse Large B-Cell Lymphoma Market report provides current treatment practices, Diffuse Large B-Cell Lymphoma emerging drugs, and Diffuse Large B-Cell Lymphoma market share of the individual therapies, current and forecasted 7MM Diffuse Large B-Cell Lymphoma market size from 2019 to 2032. The Diffuse Large B-Cell Lymphoma market report also covers current Diffuse Large B-Cell Lymphoma treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

The Diffuse Large B-cell Lymphoma market is driven by factors such as Rising Incidence among Aging population, Increase in R&D, and CAR-T therapies approvals.

Key takeaways from the Diffuse Large B-Cell Lymphoma Market Research Report

• According to the estimates, the highest market size of Diffuse Large B-Cell Lymphoma is from the United States, in 2021 and is anticipated to grow at a CAGR of 10.4%.

• The total Diffuse Large B-Cell Lymphoma market size in the 7MM is USD 3,700 million in 2021 and is projected to grow during the forecast period (2022-2032).

• The leading Diffuse Large B-Cell Lymphoma Companies include include AstraZeneca, Bristol-Myers Squibb, Seattle Genetics/Takeda, ADC Therapeutics, SymBio Pharmaceuticals, Denovo Biopharma, Merck, Amgen, TG Therapeutics, Bayer and others.

• Promising Diffuse Large B-Cell Lymphoma Pipeline Therapies in various stages of development include Rituximab (RTX), Tafasitamab, Bendamustine (BEN), KTE-C19, Atezolizumab, Cyclophosphamide, Fludarabine, Ibrutinib, Lenalidomide, VELCADE, Blinatumomab, Tisagenlecleucel, INCB053914, INCB050465, and others.

Explore more information on the latest breakthroughs in the Diffuse Large B-Cell Lymphoma Treatment Landscape and Diffuse Large B-Cell Lymphoma Market Size @ https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Recent Developmental Activities in the Diffuse Large B-Cell Lymphoma Treatment Landscape

• The FDA recently authorised Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL).

• In June 2020, Karyopharm's Selinexor, selective Inhibitor of Nuclear Export (SINE), has entered the DLBCL market as the third line of therapy and has the potential to treat the patients who are resistant to CAR-T cell therapies.

• In October 2017, the FDA granted approval to YESCARTA for treating adult patients with R/R LBCL after two or more lines of systemic therapy. In October 2022, Gilead announced that European Commission has approved the use of YESCARTA to treat adult patients with Diffuse Large B-cell Lymphoma and HGBL who relapse within 12 months from completion of or are refractory to, first-line chemo immunotherapy. The company is planning to file the application for YESCARTA in 1L setting on the basis of ZUMA-23 in 2025 or beyond.

• The FDA granted accelerated approval to XPOVIO for adult patients with R/R DLBCL, not otherwise specified, including Diffuse Large B-cell Lymphoma arising from follicular lymphoma, after at least two lines of systemic therapy. In November 2018, Karyopharm's selinexor received FTD from FDA to treat patients with R/R DLBCL.

• In June 2019, the US FDA granted accelerated approval to POLIVY (polatuzumab vedotin-piiq), in combination with the chemotherapy bendamustine and a rituximab product (known as "BR"), to treat adult patients with Diffuse Large B-cell Lymphoma that has progressed or returned after at least two prior therapies. In the May 2022, POLIVY combination received EU approval for previously untreated Diffuse Large B-cell Lymphoma.

Diffuse Large B-Cell Lymphoma Overview

Diffuse Large B-cell Lymphoma (DLBCL) is an aggressive (fast-growing) and the most common type of non-Hodgkin's lymphoma that can arise in lymph nodes or outside of the lymphatic system (such as in gastrointestinal tract, testes, thyroid, skin, breast, bone, or brain). Often, the first sign of DLBCL includes painless, rapid swelling in the neck, underarms, or groin that is caused by enlarged lymph nodes. For some patients, the swelling may be painful. Other symptoms may include night sweats, fever, and unexplained weight loss. Patients may notice fatigue, loss of appetite, shortness of breath, or pain. Generally, it has been observed that DLBCL affects patients of all age groups with a wide range of presentations concerning localization, morphology, and molecular mechanisms.

Diffuse Large B-Cell Lymphoma Epidemiology Segmentation in the 7MM
• Diffuse Large B-Cell Lymphoma Incident Population
• Diffuse Large B-Cell Lymphoma Gender-specific Population
• Diffuse Large B-Cell Lymphoma Age-specific Population
• Diffuse Large B-Cell Lymphoma Type-specific Population
• Diffuse Large B-Cell Lymphoma Stage-specific Population

Find new updates of the Diffuse Large B-cell Lymphoma Market Trends of the report Diffuse Large B-cell Lymphoma Market Forecast @ https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diffuse Large B-cell Lymphoma Market Landscape

Several options are available for B-cell Lymphoma treatment such as chemotherapy, radiation, and immunotherapy. Chemotherapy is the main way to treat most types of B-cell NHL. A combination of chemotherapy and the monoclonal antibody rituximab (Rituxan), with or without radiation therapy, can result in disease remission in a large number of patients with this form of lymphoma. The most widely used frontline regimens used is the combination of R-CHOP [rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone]. The R-CHOP is usually given every 3 weeks for a total of 6 cycles.

Diffuse Large B-cell Lymphoma Marketed Drugs
• YESCARTA (axicabtagene ciloleucel): Kite Pharma (a subsidiary of Gilead Sciences)
• KYMRIAH (tisagenlecleucel): Novartis
• XPOVIO (selinexor): Karyopharm
• POLIVY (polatuzumab vedotin-piiq): Roche/Chugai Pharmaceuticals

Get to know more information about diffuse large b-cell lymphoma clinical trials analysis of the report @ https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Diffuse Large B-cell Lymphoma Emerging Drugs
• Epcoritamab: AbbVie and Genmab
• Glofitamab: Roche
• ALLO-501A: Allogene Therapeutics
• LUNSUMIO (mosunetuzumab): Roche and Biogen
• Zamtocabtagene autoleucel (MB-CART2019.1): Miltenyi Biomedicine

Diffuse Large B-cell Lymphoma Market Outlook

Diffuse large B-cell lymphoma (DLBCL) is an aggressive form of non-Hodgkin lymphoma for which a cure is usually the therapeutic goal of optimal treatment. There are several treatment options for Diffuse large B-cell lymphoma, which include chemotherapy, radiation, and immunotherapy. The aforementioned treatment modalities have been used, alone or in combination, in the last decades to treat DLBCL. Chemotherapy is the main way to treat Diffuse large B-cell lymphoma. The market growth over the forecast period is also being driven by an increase in pipeline candidates for the development of therapies for better recovery of Diffuse large B-cell lymphoma. Rituximab's approval altered the Diffuse large B-cell lymphoma therapeutic landscape. For DLBCL patients, chemo immunotherapy is the standard of care. In addition, numerous drugs that have recently been approved have transformed the treatment landscape for individuals with R/R DLBCL in 2L and 3L.

For more information about this Diffuse Large B-cell Lymphoma market report visit Diffuse Large B-cell Lymphoma Market Research Report @ https://www.delveinsight.com/sample-request/diffuse-large-b-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Diffuse Large B-Cell Lymphoma Market Research Report

• Coverage- 7MM

• Diffuse Large B-Cell Lymphoma Companies- Morphosys, Incyte, AstraZeneca, Gilead Life Sciences, Novartis, Karyopharm therapeutics, Bristol-Myers Squibb, Celgene, Seattle Genetics, Takeda, ADC Therapeutics, SymBio Pharmaceuticals, Denovo Biopharma, Merck, Amgen, TG Therapeutics, Bayer, Debiopharm International, Cellectar Bioscience, Hoffmann-La Roche, Autolus Therapeutics, TCR2 Therapeutics, Regeneron Pharmaceuticals, and several others.

• Diffuse Large B-Cell Lymphoma Pipeline Therapies- Rituximab (RTX), Tafasitamab, Bendamustine (BEN), KTE-C19, Atezolizumab, Cyclophosphamide, Fludarabine, Ibrutinib, Lenalidomide, VELCADE, Blinatumomab, Tisagenlecleucel, INCB053914, INCB050465, and others.

• Diffuse Large B-Cell Lymphoma Market Dynamics: Diffuse Large B-Cell Lymphoma Market Drivers and Barriers

Table of Content
1. Key Insights
2. Diffuse Large B-Cell Lymphoma Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Diffuse Large B-Cell Lymphoma Market Overview at a Glance in the 7MM
7. Diffuse Large B-Cell Lymphoma Disease Background and Overview
8. Diffuse Large B-Cell Lymphoma Treatment and Guidelines
9. Diffuse Large B-Cell Lymphoma Epidemiology and Patient Population of 7MM
10. Patient Journey
11. Key Endpoints in Diffuse Large B-Cell Lymphoma
12. Diffuse Large B-Cell Lymphoma Marketed Drugs
13. Diffuse Large B-Cell Lymphoma Emerging Drugs
14. Diffuse Large B-Cell Lymphoma: 7MM Market Analysis
15. Diffuse Large B-Cell Lymphoma Unmet Needs
16. Diffuse Large B-Cell Lymphoma SWOT Analysis
17. KOL Views
18. Diffuse Large B-Cell Lymphoma Market Access and Reimbursement
19. Appendix
20. DelveInsight Capabilities
21. Disclaimer
22. About DelveInsight

Discover more information on the Diffuse Large B-Cell Lymphoma Market Dynamics and Diffuse Large B-Cell Lymphoma Market Drivers and Barriers @ https://www.delveinsight.com/report-store/diffuse-large-b-cell-lymphoma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.